A smart molecule uses the toxic environment of a cancer cell to change its own shape and find a new way to kill the tumor.
April 24, 2026
Original Paper
ROS-Programmed Intracellular Reaction Pathway Switching Enables Selective Nuclear Targeting of Nucleic Acids in Cancer Cells
ChemRxiv · chemrxiv.15002311/v1
The Takeaway
Most cancer drugs fail because the cell's trash cans, called lysosomes, trap and destroy them before they work. This new prodrug reacts with the high levels of oxidative stress inside cancer cells to switch its chemical pathway. This transformation allows the drug to escape the trash cans and head straight for the cell's nucleus and mitochondria. It essentially uses the tumor's own defense mechanisms against itself to ensure delivery. This precision ensures that only cancer cells are targeted while healthy cells are left alone.
From the abstract
Selective chemical targeting of nucleic acids (NAs) in cancer cells remains constrained by the poor cytotoxic selectivity of classical NAs-reactive drugs for malignant over healthy proliferating tissues. Although elevated intracellular reactive oxygen species (ROS) provide a basis for conditional drug activation, directing ROS-responsive chemistry toward ROS-poor compartments such as the nucleus has remained a fundamental challenge. Here we report an ROS-programmed prodrug (5) that undergoes sti